BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 3, 2002
View Archived Issues
Myogen Adds $14M To Series D To Support Late-Stage Products
Read More
Analysis Of Gene Expression In Human Eyeballs Reveals Never- Seen Inherited Genetic Mutants
Read More
Other News To Note
Read More
Correction
Read More
ImClone Suffers Erbitux Setback, Says It Won t Need New Trials
Analysts say the FDA s failure to accept ImClone Systems Inc. s rolling biologics license application for Erbitux in irinotecan-refractory colorectal cancer is expected to delay market launch by about six months.
Read More